Joel Embiid's 2025-2026 NBA MVP Hopes Diminished by Injury, Market Nears 'No' Resolution
A Polymarket predicting Joel Embiid's 2025-2026 NBA MVP victory is trading at near-zero odds for 'Yes,' as the star center's extensive injury absence renders him ineligible for the award under the NBA's 65-game rule.
The Polymarket regarding Joel Embiid's chances of winning the 2025-2026 NBA Most Valuable Player (MVP) award is signaling a near-certain 'No' resolution, with the 'Yes' outcome currently trading at a minuscule 0.0005. This reflects a stark reality: Embiid's season has been severely hampered by injuries, making him ineligible for the prestigious award.
As of March 23, 2026, Embiid has played in only 33 games during the 2025-2026 NBA regular season. He has been sidelined for 13 consecutive games with a right oblique strain, an injury sustained on February 28, 2026, and has not seen action in March. This follows a previous season (2024-2025) where his campaign was also cut short due to a knee injury.
Crucially, the NBA implemented a 65-game minimum threshold for players to be eligible for end-of-season awards like the MVP. With only 33 games under his belt and the regular season nearing its conclusion, Embiid falls far short of this requirement, effectively ruling him out of the MVP race.
The market's resolution condition explicitly states: "If the listed player is not announced as a finalist for the 2025–26 NBA MVP award, this market will immediately resolve to 'No'." Given his ineligibility due to the games played rule, Embiid cannot be named a finalist, thus ensuring the market will resolve to 'No'.
The current MVP conversation for the 2025-2026 season heavily features other star players. Early March discussions indicate frontrunners such as Shai Gilgeous-Alexander, Nikola Jokic, Cade Cunningham, and Victor Wembanyama, with Luka Doncic also considered a strong contender. Embiid's name is conspicuously absent from these discussions, a direct consequence of his limited court time.
The substantial trading volume of over $5.6 million on this market underscores the initial interest and belief in Embiid's MVP potential. However, the dramatic shift in odds to 0.0005 for 'Yes' clearly demonstrates that traders have assimilated the critical news regarding his injury and the resulting ineligibility. While Embiid is a perennial MVP candidate when healthy, his consistent injury struggles have once again derailed a promising season, leading to the near-certain 'No' outcome for this prediction market.
Sources:
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFAXsd_oQ8HuaDVcaNTSTtZ2WDkM6I9JR7eQ2_zxkjBDsurgrgWA1FPs_OeaTA-sFl5UcN2ri7J-AkVD5OzrquvlUVTxYyTQjMoGTh5zKRWv2w1T57kWu-yzviuVoe69oxUJ6TSB5tRTNyBRtCXQQUbmSts4oGxg5UVp-WEqwjFatkmIkXz18LvrLxXeo2ZeQVMzKPz4UuwBy9Vq2iDDH7iNNzUtfhj
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE40AoUlXPpHRb2yIotkSRjTnuAFC6_Z6-KpUW3w0Wrb_MLILXJAJEyiL30Tgt-bE3nde9iPyBaQmDEmsUO3lARynyWACPllppihQPmSmPsIb3gK32MAGV49Nsl_Sfz4FLF09GYoCXYtsSherVE8DbPxmd-EeI4wPlQujqkbMEGcTxi3tl1KQhhA8QJl_uQPNqdKfJNU5jjHPHsNmYscbDp619I-9SnJWphZvXKbJteKEe-sGpIb-r2sxabK3qvY-7tnjYQu4dVZ5Y3xVL7qhWprUG2aHxl2Wp-qX5POplOKavFRCeAOraBipAuDleN0J18wHiUj7qLi5gLDCKj-QV_qIL4Ub2ROT92O4WPGsbJsKIKXYOExw==
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGtNdlx2ybCeAKrTAPTmhKl_It96Q6vFEZ85H-M2VyNe9tN9ybdjys7_D35OVTRMTTqkTFHheesnJMml37Fcq1kSKbAZv9SFjIqyHfSp-YmEbVVCYkDIbvigGlollOXBBiYmsXbmi7za5wxjO5xxzCCYiNfs9V1HLIwG2knLxSGBX9i8oq0IKs61CBEdwzTUpJmxyXnDwqRNaiSgc=
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFkazbEr6agegB3IPDv2UCc-19xses8vD7X_pF7Zthi_8gduS6D4zfpSIBzvIu3VH_Aek2cyT8-zmpm02KgfLh2l5A39ZevgoEy9lWeT7d8I9NWXwCVJp9mw224oCuhWWD6e_VAnpGDtvNel7h6RnQzApPsDS4jQ4TdoIjDy_Hzen_Nw8S_
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMmJfiI6kyGExPqGszkjSc3nmXeiJT2BFh5aYELp8-RDLB0FfC4AwAtdg-ua_IxuwxIyzntNJN89XGFT8jqWo-RZmsR44t14hSJkX7ZHhhhPC8ySosIJ1-3C9bePP9Dh9hYgDs4bSd-nHbb4RyuTjXRrpDgb8agRnD29J5sjpVS9fI66HRr6u3yvU-YpUINAEFZeQJZx5Q3LZ_czeKWnuT70pqiOvhP_J8TgM0MG1Yi-XPRJ5IjTWaggPt3po9X8ktNJ_BGnAib9QYIw==
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGoKLSE3FQXJvlxAKgQ9kYDJ5ap5qqnemn5V9l7OwIJb5wFps3D-hELCChrWtNG75eORw8Z9vqmF9pgUW_VFKJ-VgSxxK6hVlOSDo4I8fuiBD5Q4E2F9UpnJN1kNUKRMbQGrLhjyz8DbNaKTapiwdhLzL9DVUJDxSj0hLEYhulCVkD-9t8nk-X-MXCVunXaBqRe5yw=
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHxvxXlMGLnIZDk9yWJjQm6rB1X5XisMe-oRB_3sUJjA3VgoxHtpemtsEVxmDo9qdEGcWWlGnnvrBh6UUkMfK4rLVoMApca4D3oS17kjVFF7sZTYG-eQCPSQpXLhGaJdGlQz2-qig==
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNihAuTtVIY41ToVMlnojAtbuTrL7xjEZ2gHjdD4U_W46JlrRTgnbpi8XzI4-I_rD8Hedwna3kvq_ppcS1RjGX6aCNH2US2CKUUkcVcvalA9X-twzn9zZVPLfIlPhHK36gcWh5Di-m0eJctHguk7mDEe1n5cXPSD6_SOqdDg8=
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFp5F9DTGOhIAAbbFkOfyXyxQDCXzNQ-ivB7E2-hqqC7pKRJ2ybED1eVcl7QCE7QlfWOxLOXeb6gT5jmbk3026as6XMIa9202F6_DhIsw7SMavoilryeIAV6SrOg7sn6wGgt3cLJw3PAecjuYwZid-XUtbPJ8kI3M8UPHquvGQ=
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFTsmZGuHHMqJxTYEGO1VKigc4xOCwFkP1muFkhpgu_BGhxkyBrgoTI6EBwko4u41jfbnwDgYdtlng_yrQb33uJKg0vbTT6Sb0bmTkOrzLokAixNVUD3pzxJZC37scpVoesOl3LG3dlsFCgV7wwnin8AXDbk_6298ASRcdHp3LmLF9_002cDupTlraAC_K_2RwOaANCAtnnG7vovqSvIGFmAICssQ==
- https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZCkGFWi8K9NRdt-tYPM7jQ6HREJLUJR0MExjDjUA8Gcrw-RUktj55y-Esl8o-hf1goYd_7MY0JVpOPbBQ2OZkFutr9DuTxKm7QkccfQkd47BCi7ABlThBPwAgBXO_Lk0fRv4JE_ZgYN-J8LG3FALS6DG5DsVxLp9UN5a2ovC6c_Zwg_crP3ynWBRH99Dl_k5FZtkOtlnXqzDvhGm7r2c4sMDifG_ZRnMQi-zegHORI769kEye1agMNPUC8I1_wKKEWC1e8040-2IpRCF3
Market data fetched at 2026-03-24 12:16 UTC | Polymarket ID: 564174
This article is generated by AI for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment decisions. Data sourced from Polymarket and public web sources.